A gene therapy subject in an early human trial to treat arthritis has died, causing the experiment to be halted. Very sad. But such are the risks in human trials, which sometimes puts people in potential peril in the effort to get cutting edge medical treatments to clinical use. (There are, of course, cases in which known risks are not disclosed, as in the 1999 gene therapy death of Jesse Gelsinger, which is not part of the usual process.)
There has been so much hope placed in this biotechnological approach, but this isn’t the first such death, and it may indicate that it will be a very long time before this potentially promising treatment modality is available—if ever.
This event should remind us that biotechnology seeks to harness the power of sheer biology. That can be risky, which is why people should be wary. We must take this one step at a time.
YOU MIGHT ALSO LIKE
Rome and the Church in the United States
Archbishop Michael J. Curley of Baltimore, who confirmed my father, was a pugnacious Irishman with a taste…
Marriage Annulment and False Mercy
Pope Leo XIV recently told participants in a juridical-pastoral formation course of the Roman Rota that the…
Undercover in Canada’s Lawless Abortion Industry
On November 27, 2023, thirty-six-year-old Alissa Golob walked through the doors of the Cabbagetown Women’s Clinic in…
